- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07507760
Decitabina Oral más Ivosidenib como Primera Línea para Pacientes Adultos Mayores/No Aptos con LMA (DECISIVO)
Un ensayo clínico de fase II, multicéntrico y abierto que evalúa la eficacia y seguridad de decitabina oral más ivosidenib en pacientes adultos con leucemia mieloide aguda recién diagnosticada mayores de 60 años y/o que no son elegibles para quimioterapia de inducción estándar
The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are:
- Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment.
- Determine the incidence and severity of all adverse events (AEs).
All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
A total of 50 participants will be assigned to the single treatment arm which will have treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5.
Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.
Participants will continue their study treatment until documented disease progression per Investigator assessment, unacceptable toxicity, withdrawal of consent, the subject meets other protocol criteria for discontinuation or study completion (whichever occurs first).
Participants who are considered eligible for an allogeneic stem cell transplant after achieving CR/CRi will perform a pre-transplant visit into the study, collecting MRD stats and characteristics of transplant. They will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. If they do not resume ivosidenib they will perform end of trial visit (and if this is not possible the pre-transplant visit will be considered as en of trial visit).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Pau Montesinos
- Número de teléfono: +34 96 1244925
- Correo electrónico: montesinos_pau@gva.es
Copia de seguridad de contactos de estudio
- Nombre: Juan José Lahuerta
- Correo electrónico: jjlahuerta@telefonica.net
Ubicaciones de estudio
-
-
-
Albacete, España, 02006
- Aún no reclutando
- Complejo Hospitalario de Albacete
-
Investigador principal:
- Jesús Lorenzo Algarra Algarra
-
Alicante, España
- Aún no reclutando
- Hospital General Universitario Dr. Balmis
-
Investigador principal:
- Carmen Botella, Dr
-
Burgos, España, 09006
- Reclutamiento
- Hospital Universitario de Burgos
-
Investigador principal:
- Jorge Labrador
-
Cáceres, España
- Reclutamiento
- Hospital San Pedro Alcántara
-
Contacto:
- Juan Bergua
-
Córdoba, España, 14004
- Reclutamiento
- Complejo Hospitalario Regional Reina Sofía
-
Investigador principal:
- Josefina Serrano López
-
Las Palmas, España
- Aún no reclutando
- Hospital Universitario de Gran Canaria Doctor Negrín
-
Contacto:
- Carlos Rodríguez
-
Las Palmas de Gran Canaria, España
- Aún no reclutando
- Hospital Universitario de Canarias
-
Investigador principal:
- Carolina Lacalzada
-
Lugo, España
- Aún no reclutando
- Hospital Universitario Lucus Augusti
-
Investigador principal:
- Aitor Abuín, Dr
-
Madrid, España
- Aún no reclutando
- H. 12 de Octubre
-
Contacto:
- Pilar Martínez Sánchez
-
Madrid, España, 28040
- Aún no reclutando
- Fundación Jiménez Díaz
-
Investigador principal:
- José Luis López Lorenzo
-
Madrid, España
- Aún no reclutando
- Hospital Univeristario Ramón y Cajal
-
Contacto:
- Pilar Herrera
-
Málaga, España
- Reclutamiento
- Hospital Virgen de la Victoria
-
Contacto:
- Maria García Fortes, Dr
-
Seville, España
- Reclutamiento
- Hospital Universitario Virgen Del Rocío
-
Contacto:
- Eduardo Rodríguez Arbolí
-
Investigador principal:
- Eduardo Rodríguez Arbolí
-
Valencia, España
- Aún no reclutando
- H. Dr. Peset
-
Contacto:
- María José Sayas
-
Sub-Investigador:
- María Pedreño, MD
-
Valencia, España
- Reclutamiento
- Hospital Universitari i Politècnic La Fe
-
Investigador principal:
- Irene Navarro
-
-
-
-
-
Aveiro, Portugal
- Aún no reclutando
- ULS Região de Aveiro
-
Contacto:
- Cátia Sol dos Reis
-
Funchal, Portugal
- Aún no reclutando
- Hospital Central do Funchal
-
Contacto:
- Rebeca Brito
-
Lisbon, Portugal
- Aún no reclutando
- Hospital Santa Maria
-
Contacto:
- Joana Brioso
-
Lisbon, Portugal
- Aún no reclutando
- ULS São José
-
Contacto:
- Luís Monteiro
-
Porto, Portugal
- Aún no reclutando
- Hospital Pedro Hispano
-
Contacto:
- Ilídia Moreira
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Morphological diagnosis of AML (WHO criteria 2022)
-
Newly diagnosed AML.
-
IDH1 R132 mutations (centrally assessed by PCR and NGS). A patient will be allowed to be included with local result after approval of the medical monitor.
-
Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2 if ≥ 60 years of age, or 0 to 3 if ≥ 18 to 60 years.
-
Age ≥ 18 years with comorbidities contraindicating intensive chemotherapy; or age ≥ 60 years.
-
≥ 60 years of age;
-
or ≥ 18 to 60 with at least one of the following co-morbidities:
- ECOG Performance Status of 2 or 3;
- Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 55% or chronic stable angina;
- DLCO ≤ 65% or FEV1 ≤ 65% or significant history of chronic pulmonary obstructive;
- Creatinine clearance ≥ 25 mL/min to < 50 ml/min
- Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN
- Non active/controlled prior neoplastic disease
- Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the PETHEMA medical monitor before study enrolment (e.g, prior MDS or MPS, high-risk cytogenetics)
-
-
Patients <70 years, with favorable risk AML according to ELN will be included only if they are not candidates to standard treatment with intensive chemotherapy.
-
Adequate renal function as demonstrated by a creatinine clearance ≥ 25 mL/min (calculated by the Cockcroft Gault formula).
-
Adequate liver function as demonstrated by: aspartate aminotransferase (AST) ≤ 5.0 × ULN, alanine aminotransferase (ALT) ≤ 5.0 × ULN, bilirubin ≤ 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor).
-
Subject has a white blood cell count < 30 × 109/L (Hydroxyurea is permitted to meet this criterion)
-
Female subjects must be either postmenopausal OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control. Female subjects of childbearing potential must have negative results for pregnancy tests performed along the study (screening and every three cycles). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
-
Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception.
-
Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
Exclusion Criteria:
- Subject has history of myeloproliferative neoplasm [MPN] with BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
- Prior therapy for AML (except hydroxiurea).
- Genetic diagnosis of acute promyelocytic leukemia.
- Subject is known to be positive for HIV (HIV testing is not required.)
- Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required).
- Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients that in the opinion of the investigator would adversely affect his/her participating in this study.
- Any severe uncontrolled systemic infection.
- Subject has a history of other malignancies within 1 year prior to study entry which is not controlled and/or requiring active therapy which may compromise the administration of IVO and oral decitabine.
- Creatinine clearance <25 mL/min (calculated by the Cockcroft-Gault formula).
- Inadequate liver function as demonstrated by AST or ALT > 5.0 × ULN, or bilirubin > 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor)
- Subject has a white blood cell count > 30 × 109/L that is not controlled using hydrea or 1 gr/sqm/day per 1 day of cytarabine.
- Contraindications for IVO or oral decitabine according to the SmPC.
- Patient has a heart rate-corrected QT interval using Fridericia's method QT for corrected heart rate (QTcF) ≥450 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., hypokalemia, family history of long QT interval syndrome). Patients with prolonged QTcF interval in the setting of bundle branch block may participate in the trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Decitabine+Ivosidenib
Participants will receive treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5. Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction. Participants who achieve CR/CRi can be submitted to allogeneic stem cell transplant and will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. |
Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle 0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis Only for those participants achieving CR/CRi |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of CR/CRi
Periodo de tiempo: 3 years
|
To assess the rates of Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) of participants treated with Ivosidenib plus Decitabine |
3 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate CR/CRi compared to historical cohort
Periodo de tiempo: 3 years
|
To evaluate the CR (Complete Remission)/CRi (Complete Remission with incomplete marrow recovery) rates after 2, 3 and 6 cycles of Ivosidenib and oral Decitabine, and compare with a matched historical cohort. |
3 years
|
|
OS compared to historical cohort
Periodo de tiempo: 3 years
|
To assess OS (overall survival, measured as the number of days from the date of enrollment to the date of death, whatever the cause of death) and compare the median between Ivosidenib with oral Decitabine and a matched historical cohort. |
3 years
|
|
EFS compared to historical cohort
Periodo de tiempo: 3 years
|
To evaluate EFS (event-free survival, defined as the number of days from enrollment until the date of progressive disease, relapse from CR or CRi, failure to achieve CR or CRi, or death from any cause) and compare with a matched historical control cohort |
3 years
|
|
Hematologic and non-hematologic toxicity and AE
Periodo de tiempo: 3 years
|
Toxicity and adverse events (AE) will be recorded and evaluated to determine treatment safety. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.019. |
3 years
|
|
Quality of CR
Periodo de tiempo: 3 years
|
The quality of the Complete Remission (CR) will measured by the study of minimal residual disease percentages in the bone marrow using multiparametric flow cytometry and Next Generation Sequencing |
3 years
|
|
Early mortality
Periodo de tiempo: 3 years
|
To evaluate the mortality rate during the first 60 days of treatment |
3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Pau Montesinos, Hospital Universitari i Politèncic La Fe
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Ácidos nucleicos, nucleótidos y nucleósidos
- Amidas
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Compuestos AZA
- Nucleósidos
- Ribonucleósidos
- Arabinonucleósidos
- Azacitidina
- Urea
- Decitabina
- Citarabina
- Hidroxiurea
- iosidenib
- cedazuridina
Otros números de identificación del estudio
- DECISIVO
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .